Global drugmakers commit billions to US manufacturing
Major healthcare firms have announced billions of dollars in investments to expand United States manufacturing and research infrastructure. Companies aim to strengthen domestic supply chains and navigate trade policies.
Xurve View
Insights:
Xurve View
Global healthcare giants have committed roughly $500 billion to expand manufacturing and research across the United States, preparing for a shifting trade environment. Drugmakers are pouring capital into domestic infrastructure to mitigate supply-chain risks and secure tariff exemptions. The wave of investments follows federal administration pressure to onshore medical production and curb reliance on foreign facilities.
